{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.17","value":"124.56"},{"groupId":"OG001","spread":"23.98","value":"126.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.91","value":"-0.74"},{"groupId":"OG001","spread":"13.89","value":"1.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"title":"CFB at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.80","value":"-12.16"},{"groupId":"OG001","spread":"16.23","value":"22.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"CFB at Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.61","value":"-1.68"},{"groupId":"OG001","spread":"15.23","value":"1.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"title":"CFB at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.55","value":"0.02"},{"groupId":"OG001","spread":"18.29","value":"0.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"title":"CFB at End of Induction Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.73","value":"5.10"},{"groupId":"OG001","spread":"15.45","value":"3.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"131"}],"units":"Participants"}],"title":"CFB at Follow-up Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.29","value":"5.40"},{"groupId":"OG001","spread":"17.76","value":"5.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"title":"CFB at Follow-up Month 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.01","value":"5.03"},{"groupId":"OG001","spread":"15.96","value":"6.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"title":"CFB at Follow-up Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.27","value":"1.48"},{"groupId":"OG001","spread":"15.61","value":"5.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"CFB at Follow-up Month 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.39","value":"4.58"},{"groupId":"OG001","spread":"16.89","value":"5.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"CFB at Follow-up Month 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.84","value":"2.97"},{"groupId":"OG001","spread":"18.93","value":"5.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"CFB at Follow-up Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.85","value":"3.18"},{"groupId":"OG001","spread":"17.06","value":"5.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"CFB at Follow-up Month 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.98","value":"2.25"},{"groupId":"OG001","spread":"16.97","value":"7.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"title":"CFB at Follow-up Month 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.38","value":"2.16"},{"groupId":"OG001","spread":"18.27","value":"6.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"title":"CFB at Follow-up Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.34","value":"-0.89"},{"groupId":"OG001","spread":"18.90","value":"5.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"title":"CFB at Follow-up Month 20"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.03","value":"2.15"},{"groupId":"OG001","spread":"17.98","value":"4.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"title":"CFB at Follow-up Month 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.74","value":"-2.13"},{"groupId":"OG001","spread":"18.75","value":"5.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"CFB at Follow-up Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.60","value":"2.15"},{"groupId":"OG001","spread":"20.11","value":"2.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"CFB at Final follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.67","value":"1.22"},{"groupId":"OG001","spread":"20.30","value":"5.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"CFB at Extension Follow Up Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.73","value":"4.92"},{"groupId":"OG001","spread":"19.24","value":"6.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"48"}],"units":"Participants"}],"title":"CFB at Extension Follow Up Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.88","value":"9.69"},{"groupId":"OG001","spread":"20.32","value":"6.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"CFB at Extension Follow Up Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}],"units":"Participants"}],"description":"FACT-Lym total score is the sum of physical well-being score (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and Lymphoma sub-scale (15 items); responses to each item range from 0, \"Not at all\" to 4, \"Very much\". Total score ranges from 0-168. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEAN","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24","title":"CFB in FACT-Lym Total Score","type":"SECONDARY","unitOfMeasure":"Units on a scale"}